U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07532603) titled 'A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris' on April 03.
Brief Summary: This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Study Start Date: March 19
Study Type: INTERVENTIONAL
Condition:
Lichen Planopilaris
Intervention:
DRUG: Oral Brepocitinib
Oral
DRUG: Placebo
Oral
Recruitment Status: RECRUITING
Sponsor: Priovant Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....